PrevEp is a Bethesda biotechnology company founded in 2018 by epilepsy researchers whose discoveries include Keppra and ezogabine. Its seven co-founders bring more than 150 years of combined experience to developing treatments for people with difficult unmet needs in epilepsy, including an intravenous topiramate program for neonatal seizures.
FDA Orphan Drug Designation
compliance_program
Orphan Drug Designation in the United States and Europe
compliance_program
505(b)(2) Regulatory Pathway
compliance_program